The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $8.69 in the prior trading day, Bausch Health Companies Inc (NYSE: BHC) closed at $8.45, down -2.76%. In other words, the price has decreased by $-2.76 from its previous closing price. On the day, 2.33 million shares were traded. BHC stock price reached its highest trading level at $8.8 during the session, while it also had its lowest trading level at $8.42.
Ratios:
Our goal is to gain a better understanding of BHC by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.99. For the most recent quarter (mrq), Quick Ratio is recorded 0.94 and its Current Ratio is at 1.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on September 20, 2023, Upgraded its rating to Buy and sets its target price to $16 from $9 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Carson Seana sold 6,313 shares for $9.80 per share. The transaction valued at 61,867 led to the insider holds 499,905 shares of the business.
Carson Seana sold 220 shares of BHC for $1,624 on Dec 05 ’23. The EVP, General Counsel now owns 382,925 shares after completing the transaction at $7.38 per share. On Nov 06 ’23, another insider, Carson Seana, who serves as the EVP, General Counsel of the company, sold 43 shares for $7.61 each. As a result, the insider received 327 and left with 384,836 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BHC now has a Market Capitalization of 3098386688 and an Enterprise Value of 25677731840. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.35. Its current Enterprise Value per Revenue stands at 2.932 whereas that against EBITDA is 8.9.
Stock Price History:
The Beta on a monthly basis for BHC is 0.91, which has changed by 0.18679774 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, BHC has reached a high of $11.46, while it has fallen to a 52-week low of $5.57. The 50-Day Moving Average of the stock is -8.50%, while the 200-Day Moving Average is calculated to be 1.82%.
Shares Statistics:
The stock has traded on average 2.76M shares per day over the past 3-months and 4234100 shares per day over the last 10 days, according to various share statistics. A total of 365.24M shares are outstanding, with a floating share count of 356.59M. Insiders hold about 2.41% of the company’s shares, while institutions hold 79.13% stake in the company. Shares short for BHC as of 1711584000 were 22495263 with a Short Ratio of 8.15, compared to 1709164800 on 24637712. Therefore, it implies a Short% of Shares Outstanding of 22495263 and a Short% of Float of 8.129999999999999.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 6.52.
Earnings Estimates
Bausch Health Companies Inc (BHC) is currently under the scrutiny of 4 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of $0.69 for the current quarter, with a high estimate of $0.85 and a low estimate of $0.59, while EPS last year was $0.52. The consensus estimate for the next quarter is $0.96, with high estimates of $1.05 and low estimates of $0.87.
Analysts are recommending an EPS of between $4.18 and $3.66 for the fiscal current year, implying an average EPS of $3.93. EPS for the following year is $4.18, with 5 analysts recommending between $5.02 and $3.22.
Revenue Estimates
4 analysts predict $2.15B in revenue for the current quarter. It ranges from a high estimate of $2.17B to a low estimate of $2.13B. As of the current estimate, Bausch Health Companies Inc’s year-ago sales were $1.97B, an estimated increase of 9.30% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $2.35B, an increase of 8.40% less than the figure of $9.30% in the same quarter last year. There is a high estimate of $2.37B for the next quarter, whereas the lowest estimate is $2.33B.
A total of 6 analysts have provided revenue estimates for BHC’s current fiscal year. The highest revenue estimate was $9.44B, while the lowest revenue estimate was $9.31B, resulting in an average revenue estimate of $9.39B. In the same quarter a year ago, actual revenue was $8.76B, up 7.30% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $9.6B in the next fiscal year. The high estimate is $9.75B and the low estimate is $9.32B. The average revenue growth estimate for next year is up 2.20% from the average revenue estimate for this year.
